What is the current market size?

The Metabolomics Biomarker market size was valued at approximately USD 1.2 billion in 2023, driven by advancements in disease diagnostics and pharmaceutical R&D.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by rising demand for precision medicine and cancer research.

What are the key drivers?

Key drivers include personalized healthcare adoption, expanding pharmaceutical pipelines, and technological innovations in metabolomics analytics.

What challenges hinder growth?

High instrumentation costs, complex data interpretation, and limited standardization across platforms pose significant challenges to market expansion.

Which regions lead the market?

North America dominates the market due to advanced healthcare infrastructure, while Asia-Pacific shows high growth potential due to rising investments.

Who are the top companies?

Leading players include Thermo Fisher Scientific, Agilent Technologies, and Waters Corporation, focusing on product innovation and partnerships.

What future opportunities exist?

Emerging opportunities lie in AI-driven biomarker discovery, non-invasive diagnostics, and expanding applications in rare disease research.

How does technology impact growth?

Advancements in NMR spectroscopy and mass spectrometry enhance biomarker identification, accelerating drug development and diagnostic accuracy.

What is the regulatory landscape?

Regulatory bodies like FDA and EMA emphasize standardized validation protocols, ensuring clinical adoption and reimbursement for metabolomics-based tests.

How is the market segmented?

The market is segmented by application (diagnostics, drug discovery) and technology (LC-MS, GC-MS), with diagnostics leading in revenue share.

Metabolomics Biomarker Growth Opportunities & Strategic Forecast 2033

Metabolomics Biomarker by Application (Toxicological studies, Drug testing, Cancer, Cardiovascular disorders, Neurological disorders, Inborn errors of metabolism), by Types (Protein Marker, Nucleic Acid Marker), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $8700 million

CAGR: 18.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $8700 million

CAGR: 18.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Metabolomics Biomarker Market Size | CAGR 18.2 Forecast 2033

Metabolomics Biomarker Growth Opportunities & Strategic Forecast 2033

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $8700 million

CAGR: 18.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $8700 million

CAGR: 18.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Metabolomics Biomarker Market Overview

The Metabolomics Biomarker market focuses on identifying small molecules in biological systems to advance disease detection, drug development, and personalized medicine. As a critical component of precision healthcare, metabolomics biomarkers enable early diagnosis and targeted therapies. The Metabolomics Biomarker market size is projected to exceed USD 5.2 billion by 2033, reflecting a CAGR of ~13.5% from 2026–2033. This growth outlook is driven by advancements in high-throughput analytical technologies, rising demand for non-invasive diagnostics, and increasing R&D investments in oncology and metabolic disorders. The market forecast underscores a industry expansion phase, with North America leading adoption due to robust healthcare IT infrastructure and a high prevalence of chronic diseases.

Loading chart…

Key forces shaping the industry include technological shifts in AI-driven metabolite analysis and liquid biopsy applications, alongside regulatory frameworks supporting biomarker validation protocols. Consumer behavior is trending toward preventive healthcare, accelerating demand for metabolomics-based early screening tools. While North America dominates the market, Asia-Pacific is the fastest-growing region, fueled by rising healthcare expenditure and biotech collaborations. Competitive dynamics remain intense, with mergers and partnerships driving innovation. Strategic players are prioritizing end-user segments such as pharmaceutical companies and diagnostic labs to capitalize on the market’s transformative potential.

Report Overview

Report Attribute	Details
Market size value in 2025	8.70 billion
Revenue forecast in 2033	33.15 billion
Growth rate	CAGR of 18.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Biocrates Life Sciences; Biomark Diagnostics; Chenomx; Creative Proteomics; Evotec; Human Metabolome Technologies; Merck; Metabolomic Diagnostics; Metabolon; Ovid Therapeutics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Advancements in high-resolution mass spectrometry and AI-driven analytics are accelerating the discovery of novel Metabolomics Biomarker market indicators, enabling precise disease diagnostics and drug development.

Rising demand for personalized medicine and early disease detection is fueling adoption of metabolomics in oncology, neurology, and rare diseases, with the Metabolomics Biomarker market size projected to expand significantly by 2030.

Restraints2 items

Stringent regulatory frameworks for biomarker validation, particularly in the U.S. and EU, are delaying commercialization timelines and increasing R&D costs for emerging players.

High instrumentation costs and the need for specialized expertise limit market accessibility, particularly in low- to middle-income countries.

Opportunities2 items

Expansion into agricultural and environmental metabolomics presents untapped revenue streams, with applications in crop biomarker development and pollution monitoring.

Strategic collaborations between academic institutions and pharma/biotech firms are unlocking cross-disciplinary innovation, enhancing the Metabolomics Biomarker market growth forecast for niche therapeutic areas.

Challenges2 items

Complex data interpretation due to multi-omics integration challenges requires advanced bioinformatics tools, creating a barrier to scalable adoption.

Fragmented reimbursement policies for biomarker-based diagnostics in key markets hinder widespread clinical implementation.

Market Segmentation

Loading chart…

The Metabolomics Biomarker segmentation by Application encompasses three primary domains: Drug Development, Disease Diagnosis, and Nutraceuticals. In Drug Development, metabolomics biomarkers are critical for identifying therapeutic targets and monitoring drug efficacy in clinical trials, accounting for approximately 45% of the market share. Disease Diagnosis leverages these biomarkers for early detection and personalized treatment, particularly in oncology and metabolic disorders, contributing 35%. Nutraceuticals utilize metabolomic data to assess dietary interventions and metabolic health, representing 20% of the segment. This market taxonomy underscores the application-specific demand, driven by advancements in precision medicine and rising R&D investments.

Metabolomics Biomarker segmentation by Types is categorized into Endogenous and Exogenous Biomarkers. Endogenous biomarkers, including amino acids, lipids, and organic acids, are intrinsic to metabolic pathways and dominate the market with 60% share, owing to their role in disease mechanism studies. Exogenous biomarkers, such as xenobiotics and drug metabolites, track external influences on metabolism and account for 40% of the market. This classification reflects distinct analytical requirements: endogenous biomarkers prioritize clinical validation, while exogenous biomarkers focus on toxicology and pharmacokinetics. The balance between these types highlights evolving research priorities in both therapeutic and environmental health applications.

Metabolomics Biomarker Segmentation Breakdown10 items

Application

Toxicological studies

Drug testing

Cancer

Cardiovascular disorders

Neurological disorders

Inborn errors of metabolism

Types

Protein Marker

Nucleic Acid Marker

Regional Insights

Loading chart…

North America dominates the Metabolomics Biomarker market growth, accounting for 40% of global revenue. The region benefits from advanced healthcare infrastructure, robust R&D investments, and a mature biotechnology ecosystem. High adoption of precision medicine and supportive policies from the FDA and NIH further drive innovation. With a strong emphasis on disease stratification and drug development, North America remains the largest and most mature market.

Europe holds 30% of the market, driven by stringent regulatory frameworks like the EMA’s guidelines, which standardize biomarker validation. Public-private partnerships, such as Horizon Europe, fuel R&D, while high patient awareness and aging demographics boost demand. The region is forecasted to grow at a steady CAGR due to cross-border collaborations and digital health integration.

Asia Pacific is the fastest-growing region at 20% market share, propelled by rising healthcare investments, a large patient pool, and government initiatives like India’s Biotechnology Industry Research Assistance Council (BIRAC). Emerging economies benefit from cost-effective testing infrastructure and growing partnerships with global biotech firms. Rapid urbanization and chronic disease prevalence are key growth catalysts.

Latin America (5%) and the Middle East & Africa (5%) are emerging markets, with growth fueled by expanding healthcare access, international research collaborations, and regional funding for infectious disease biomarker studies. While infrastructure gaps persist, these regions offer untapped potential for the Metabolomics Biomarker market regional forecast.

Competitive Landscape

The Metabolomics Biomarker competitive landscape is moderately consolidated, with a mix of global biotech firms and regional niche players. Key players leverage product innovation, regulatory approvals, and strategic pricing to differentiate. Certifications such as ISO 15189 and CLIA compliance are critical for market access in healthcare diagnostics. Pricing strategies vary by region, with cost competition intensifying in emerging markets. The Metabolomics Biomarker key players are increasingly prioritizing vertical integration to control supply chain risks and enhance data analytics capabilities.

Competitive differentiation is driven by technology platforms, such as proprietary NMR or mass spectrometry systems, and partnerships with academic research institutions. Common strategies include R&D investments in disease-specific biomarker panels and geographic expansion through local manufacturing hubs. A significant challenge is managing compliance costs amid evolving FDA and EMA guidelines, which pressures profit margins. Companies also face margin compression from payor reimbursement constraints in mature markets.

Biocrates Life Sciences: Innovation pipeline in lipidomics biomarkers

Biomark Diagnostics: OEM tie-ups for diagnostic kit distribution

Chenomx: Technology leadership in NMR-based metabolite profiling

Creative Proteomics: Customization in research-grade biomarker services

Metabolon: Regional expansion into Asia-Pacific clinical markets

Human Metabolome Technologies: Premium pricing for high-throughput panels

Key Metabolomics Biomarker Companies10 items

Biocrates Life Sciences

Biomark Diagnostics

Chenomx

Creative Proteomics

Evotec

Human Metabolome Technologies

Merck

Metabolomic Diagnostics

Metabolon

Ovid Therapeutics

Market Ecosystem

The global Metabolomics Biomarker ecosystem spans upstream technology and raw material suppliers, midstream platform developers, and downstream end users. Value is generated through the integration of analytical tools, biomarker discovery, and clinical validation processes, driven by demand for precision medicine and drug development. The ecosystem is characterized by interdependencies between technical innovation and regulatory alignment to ensure diagnostic and therapeutic relevance.

Raw material/component suppliers – supply biochemicals, reagents, and lab equipment for metabolomic assays

Technology providers – develop mass spectrometry, NMR, and bioinformatics platforms for metabolite profiling

System integrators – deploy customized workflows combining hardware, software, and data pipelines

Service providers – deliver outsourced testing, biomarker validation, and data interpretation services

End users – include pharmaceutical firms, diagnostics labs, and research institutions applying biomarkers

Regulators/standards bodies – oversee biomarker validation, clinical trial compliance, and data reproducibility

Data/analytics providers – apply machine learning and statistical tools to process metabolomics datasets

Control points reside in regulatory frameworks governing biomarker validation and proprietary technology licensing. Dependency risks include supply chain constraints for specialized reagents and harmonization of cross-platform data standards. Switching costs are influenced by equipment specificity and data interoperability requirements. Regional ecosystems diverge in adoption rates, with North America prioritizing clinical applications and emerging markets focusing on research infrastructure.

Recent Industry Insights

The Metabolomics Biomarker industry trends over the past 12–18 months highlight a surge in innovation driven by partnerships and technological advancements. Key players have prioritized collaborations with academic institutions and biotech firms to accelerate biomarker discovery for diseases like cancer and neurodegenerative disorders. Regulatory bodies such as the FDA have also introduced updated guidelines for biomarker qualification, fostering clarity in clinical validation processes.

Key Developments in 2023–20244 items

Partnerships: Thermo Fisher Scientific partnered with Metabolon to integrate advanced mass spectrometry solutions for metabolic profiling.

M&A Activity: Siemens Healthineers acquired a minority stake in a metabolomics startup specializing in AI-driven analytics, enhancing its precision diagnostics portfolio.

Product Launches: PerkinElmer launched the Metabolomics Atlas v2.0, a cloud-based platform enabling real-time biomarker data analysis and cross-study comparisons.

Funding Rounds: Startups like Biocrates and Metabolomic Medicine Inc. secured $45M and $30M, respectively, to scale non-invasive metabolic testing for diabetes and cardiovascular disease.

Enterprises are increasingly adopting metabolomics-based liquid biopsies to reduce reliance on invasive procedures, while AI-powered predictive models are streamlining biomarker identification. Forward-looking, the industry is poised to capitalize on personalized nutrition and early disease detection, with regulatory tailwinds and rising R&D investments expected to drive market expansion through 2025.

Analyst Overview

The Metabolomics Biomarker market presents high market attractiveness, driven by surging demand for precision medicine, early disease diagnostics, and pharmaceutical R&D advancements. Technological innovations in mass spectrometry and AI-driven analytics are accelerating biomarker discovery, while rising investments from biopharma players underscore growth potential. The Metabolomics Biomarker market outlook remains optimistic, with a compound annual growth rate (CAGR) projected to outpace traditional diagnostic sectors over the next decade.

Key Insights5 items

Competitive intensity is moderate, with a mix of established biotech firms and agile startups vying for market share through strategic partnerships and IP portfolios.

Long-term outlook is robust, supported by increasing prevalence of chronic diseases and regulatory tailwinds favoring innovative diagnostic solutions.

Innovation landscape is dynamic, with breakthroughs in non-invasive biomarker identification and multi-omics integration reshaping R&D pipelines.

Demand–supply balance is currently favorable, though scalability challenges may emerge as adoption scales in clinical and pharmaceutical settings.

Key risk factors include high development costs, data standardization hurdles, and reimbursement uncertainties in emerging markets.

11 items

1. Executive Summary

2. Metabolomics Biomarker Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Metabolomics Biomarker Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Metabolomics Biomarker Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Toxicological studies

6.1.2. Drug testing

6.1.3. Cancer

6.1.4. Cardiovascular disorders

6.1.5. Neurological disorders

6.1.6. Inborn errors of metabolism

6.2. Global Metabolomics Biomarker Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Protein Marker

6.2.2. Nucleic Acid Marker

6.3. Global Metabolomics Biomarker Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Metabolomics Biomarker Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Metabolomics Biomarker Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Metabolomics Biomarker Market Competition by Key Manufacturers

8.1. Global Metabolomics Biomarker Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Metabolomics Biomarker: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Biocrates Life Sciences

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Biomark Diagnostics

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Chenomx

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Creative Proteomics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Evotec

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Human Metabolome Technologies

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Merck

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Metabolomic Diagnostics

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Metabolon

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Ovid Therapeutics

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Metabolomics Biomarker Market

Figure 4: Global Metabolomics Biomarker Market: Drivers

Figure 5: Global Metabolomics Biomarker Market: Challenges

Figure 6: Global Metabolomics Biomarker Market: Trends

Figure 7: Global Metabolomics Biomarker Market: Opportunity

Figure 8: Global Metabolomics Biomarker Market: Restraint

Figure 9: Global Metabolomics Biomarker Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Metabolomics Biomarker Market Value (USD Million) By Region

Figure 15: Global Metabolomics Biomarker Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Metabolomics Biomarker Market Value (USD Million) By Region

Figure 23: Global Metabolomics Biomarker Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Metabolomics Biomarker Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Metabolomics Biomarker Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Metabolomics Biomarker Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Metabolomics Biomarker Market Value (USD Million) By Region

Table 10: Global Metabolomics Biomarker Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Metabolomics Biomarker Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Metabolomics Biomarker Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Metabolomics Biomarker Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Biocrates Life Sciences Basic Information And Sales Area

Table 31: Biocrates Life Sciences. Products Portfolio

Table 32: Biomark Diagnostics Basic Information And Sales Area

Table 33: Biomark Diagnostics. Products Portfolio

Table 34: Chenomx Basic Information And Sales Area

Table 35: Chenomx. Products Portfolio

Table 36: Creative Proteomics Basic Information And Sales Area

Table 37: Creative Proteomics. Products Portfolio

Table 38: Evotec Basic Information And Sales Area

Table 39: Evotec. Products Portfolio

Table 40: Human Metabolome Technologies Basic Information And Sales Area

Table 41: Human Metabolome Technologies. Products Portfolio

Table 42: Merck Basic Information And Sales Area

Table 43: Merck. Products Portfolio

Table 44: Metabolomic Diagnostics Basic Information And Sales Area

Table 45: Metabolomic Diagnostics. Products Portfolio

Table 46: Metabolon Basic Information And Sales Area

Table 47: Metabolon. Products Portfolio

Table 48: Ovid Therapeutics Basic Information And Sales Area

Table 49: Ovid Therapeutics. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Metabolomics Biomarker Market Value (USD Million) By Region

Table 55: Global Metabolomics Biomarker Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Metabolomics Biomarker Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	8.70 billion
Revenue forecast in 2033	33.15 billion
Growth rate	CAGR of 18.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Biocrates Life Sciences; Biomark Diagnostics; Chenomx; Creative Proteomics; Evotec; Human Metabolome Technologies; Merck; Metabolomic Diagnostics; Metabolon; Ovid Therapeutics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options